The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform

W R Fair - One of the best experts on this subject based on the ideXlab platform.

  • EFFECT OF NEOADJUVANT HORMONAL THERAPY ON PROSTATIC Intraepithelial Neoplasia AND ITS PROGNOSTIC SIGNIFICANCE
    The Journal of Urology, 1999
    Co-Authors: K C Balaji, F Rabbani, H Tsai, A Bastar, W R Fair
    Abstract:

    AbstractPurpose: We studied the effect of neoadjuvant hormonal therapy on prostatic Intraepithelial Neoplasia in patients undergoing radical prostatectomy and assessed the effect of prostatic Intraepithelial Neoplasia on disease recurrence as measured by serum prostate specific antigen (PSA).Materials and Methods: A total of 278 patients with clinically localized prostate cancer were included in phase II and III studies evaluating radical prostatectomy alone versus radical prostatectomy following neoadjuvant hormonal therapy at Memorial Sloan-Kettering Cancer Center between October 1991 and August 1996. Patient data related to prostatic Intraepithelial Neoplasia were analyzed.Results: Of 275 evaluable patients 145 (52.7%) had prostatic Intraepithelial Neoplasia. Of 50 patients treated with neoadjuvant hormonal therapy (hormone group) 22 (44%) had a lower incidence of prostatic Intraepithelial Neoplasia compared to 69 of 80 controls (86.3%) (chi-square test p

  • Effect of neoadjuvant hormonal therapy on prostatic Intraepithelial Neoplasia and its prognostic significance.
    The Journal of urology, 1999
    Co-Authors: K C Balaji, F Rabbani, H Tsai, A Bastar, W R Fair
    Abstract:

    We studied the effect of neoadjuvant hormonal therapy on prostatic Intraepithelial Neoplasia in patients undergoing radical prostatectomy and assessed the effect of prostatic Intraepithelial Neoplasia on disease recurrence as measured by serum prostate specific antigen (PSA). A total of 278 patients with clinically localized prostate cancer were included in phase II and III studies evaluating radical prostatectomy alone versus radical prostatectomy following neoadjuvant hormonal therapy at Memorial Sloan-Kettering Cancer Center between October 1991 and August 1996. Patient data related to prostatic Intraepithelial Neoplasia were analyzed. Of 275 evaluable patients 145 (52.7%) had prostatic Intraepithelial Neoplasia. Of 50 patients treated with neoadjuvant hormonal therapy (hormone group) 22 (44%) had a lower incidence of prostatic Intraepithelial Neoplasia compared to 69 of 80 controls (86.3%) (chi-square test p<0.0001). Of 262 patients (95.3%) with followup PSA 44 (16.8%) had PSA recurrence at a median followup of 32 months, with a median time to recurrence of 30 months. PSA recurrence was noted in 23 of 145 patients with compared to 21 of 130 without prostatic Intraepithelial Neoplasia (chi-square test p = 0.95), and did not significantly differ between the hormone group (25 of 142, 17.6%) and controls (19 of 130, 14.6%) (chi-square test p = 0.45). While patients treated with neoadjuvant hormonal therapy had significantly lower incidence of prostatic Intraepithelial Neoplasia, neither prostatic Intraepithelial Neoplasia nor neoadjuvant hormonal therapy significantly affected PSA recurrence at a median followup of 32 months.

Ann-marie Wennberg - One of the best experts on this subject based on the ideXlab platform.

  • Penile Intraepithelial Neoplasia: results of photodynamic therapy.
    Acta dermato-venereologica, 2006
    Co-Authors: John Paoli, Annika Ternesten Bratel, Gun-britt Löwhagen, Bo Stenquist, Ola Forslund, Ann-marie Wennberg
    Abstract:

    Failure of response to treatment or recurrent disease is often noted in patients with penile Intraepithelial Neoplasia. Photodynamic therapy has recently been added to the list of treatment modalities used for this diagnosis. Our primary objective was to study the results of photodynamic therapy in the treatment of penile Intraepithelial Neoplasia in men over the age of 40 years. Ten patients aged 42-82 years with histopathologically confirmed lesions were studied. Lesions initially responded to photodynamic therapy in 7 out of 10 patients. Four of these patients presented no recurrences during a mean follow-up of 35 months, and were completely cleared after 2-8 treatments (mean 4.5 treatments). Three patients presented recurrences after treatment. No patient developed invasive penile cancer (mean follow-up 46.5 months). Photodynamic therapy is an alternative in the treatment of penile Intraepithelial Neoplasia, although prospective randomized trials are required to provide therapeutic guidelines.

J.o'd. Mcgee - One of the best experts on this subject based on the ideXlab platform.

  • Squamous Intraepithelial Neoplasia in an ovarian cyst, cervical Intraepithelial Neoplasia, and human papillomavirus.
    Human pathology, 1995
    Co-Authors: M.j Sworn, H Jones, A.t Letchworth, C. S. Herrington, J.o'd. Mcgee
    Abstract:

    A case of squamous Intraepithelial Neoplasia in an ovarian cyst in association with cervical Intraepithelial Neoplasia (CIN) III is described. In view of the association of human papillomavirus (HPV) and CIN, the possibility that HPV infection could be associated with similar changes in the ovary was postulated. The HPV genome was shown in formalin-fixed tissue of the cervical lesion by nonisotopic in situ hybridization (NISH) and by the polymerase chain reaction (PCR). However, HPV could not be shown in the ovarian lesion by NISH or PCR. On the basis of these findings there appears to be no association between HPV infection and squamous Intraepithelial Neoplasia in an ovarian cyst.

Joseph T. Santoso - One of the best experts on this subject based on the ideXlab platform.

  • risk factors for anal Intraepithelial Neoplasia in women with genital dysplasia
    Obstetrics & Gynecology, 2013
    Co-Authors: Adam C. Elnaggar, Joseph T. Santoso
    Abstract:

    OBJECTIVE To identify risk factors associated with anal Intraepithelial Neoplasia and develop a model for predicting the likelihood of anal Intraepithelial Neoplasia in heterosexual women. METHODS A prospective cohort of 327 patients from 2006 to 2011 with a biopsy-confirmed diagnosis of genital Intraepithelial Neoplasia (vulvar, vaginal, or cervical) underwent both anal cytology and anoscopy. Variables significant between those with and without anal Intraepithelial Neoplasia were identified using logistic regression. A forward stepwise regression analysis was carried out to identify a combination of variables that effectively predicted anal Intraepithelial Neoplasia. RESULTS In the cohort of analyzed patients, 64 (46.7%) women with anal Intraepithelial Neoplasia were identified, yielding a prevalence of 19.6%. Immunosuppression, vulvar dysplasia, multiple sexual partners (more than four), smoking history, and history of anal sex were positively associated with anal Intraepithelial Neoplasia (P<.05). These variables were analyzed using forward stepwise logistic regression. The final model used the presence of any two of three risk factors (vulvar Intraepithelial Neoplasia [VIN], immunosuppression, and history of anal sex) to predict 38.8% of anal Intraepithelial Neoplasia in our population. Area under the receiver operating characteristic curve for two of three of the factors was 0.708 (P<.05). This model has a negative predictive value of 88.2% (95% confidence interval [CI] 0.83-0.92) and positive predictive value of 43.1% (95% CI 0.31-0.56). CONCLUSION A simple predictive model based on the presence or absence of two of three risk factors (VIN, immunosuppression, and history of anal sex) can be used by the clinician to quantify anal Intraepithelial Neoplasia risk in women with genital dysplasia. LEVEL OF EVIDENCE II.

  • Risk factors for anal Intraepithelial Neoplasia in women with genital dysplasia.
    Obstetrics and gynecology, 2013
    Co-Authors: Adam C. Elnaggar, Joseph T. Santoso
    Abstract:

    OBJECTIVE To identify risk factors associated with anal Intraepithelial Neoplasia and develop a model for predicting the likelihood of anal Intraepithelial Neoplasia in heterosexual women. METHODS A prospective cohort of 327 patients from 2006 to 2011 with a biopsy-confirmed diagnosis of genital Intraepithelial Neoplasia (vulvar, vaginal, or cervical) underwent both anal cytology and anoscopy. Variables significant between those with and without anal Intraepithelial Neoplasia were identified using logistic regression. A forward stepwise regression analysis was carried out to identify a combination of variables that effectively predicted anal Intraepithelial Neoplasia. RESULTS In the cohort of analyzed patients, 64 (46.7%) women with anal Intraepithelial Neoplasia were identified, yielding a prevalence of 19.6%. Immunosuppression, vulvar dysplasia, multiple sexual partners (more than four), smoking history, and history of anal sex were positively associated with anal Intraepithelial Neoplasia (P

  • Anal Intraepithelial Neoplasia in women with genital Intraepithelial Neoplasia.
    Obstetrics and gynecology, 2010
    Co-Authors: Joseph T. Santoso, Mary Long, Mary Crigger, Jim Y. Wan, Hope K. Haefner
    Abstract:

    OBJECTIVE:To estimate the prevalence of anal Intraepithelial Neoplasia in heterosexual women with genital Intraepithelial Neoplasia, and to compare anal cytology with colposcopy for their effectiveness in anal Intraepithelial Neoplasia screening.METHODS:Women with confirmed Intraepithelial Neoplasia

K C Balaji - One of the best experts on this subject based on the ideXlab platform.

  • EFFECT OF NEOADJUVANT HORMONAL THERAPY ON PROSTATIC Intraepithelial Neoplasia AND ITS PROGNOSTIC SIGNIFICANCE
    The Journal of Urology, 1999
    Co-Authors: K C Balaji, F Rabbani, H Tsai, A Bastar, W R Fair
    Abstract:

    AbstractPurpose: We studied the effect of neoadjuvant hormonal therapy on prostatic Intraepithelial Neoplasia in patients undergoing radical prostatectomy and assessed the effect of prostatic Intraepithelial Neoplasia on disease recurrence as measured by serum prostate specific antigen (PSA).Materials and Methods: A total of 278 patients with clinically localized prostate cancer were included in phase II and III studies evaluating radical prostatectomy alone versus radical prostatectomy following neoadjuvant hormonal therapy at Memorial Sloan-Kettering Cancer Center between October 1991 and August 1996. Patient data related to prostatic Intraepithelial Neoplasia were analyzed.Results: Of 275 evaluable patients 145 (52.7%) had prostatic Intraepithelial Neoplasia. Of 50 patients treated with neoadjuvant hormonal therapy (hormone group) 22 (44%) had a lower incidence of prostatic Intraepithelial Neoplasia compared to 69 of 80 controls (86.3%) (chi-square test p

  • Effect of neoadjuvant hormonal therapy on prostatic Intraepithelial Neoplasia and its prognostic significance.
    The Journal of urology, 1999
    Co-Authors: K C Balaji, F Rabbani, H Tsai, A Bastar, W R Fair
    Abstract:

    We studied the effect of neoadjuvant hormonal therapy on prostatic Intraepithelial Neoplasia in patients undergoing radical prostatectomy and assessed the effect of prostatic Intraepithelial Neoplasia on disease recurrence as measured by serum prostate specific antigen (PSA). A total of 278 patients with clinically localized prostate cancer were included in phase II and III studies evaluating radical prostatectomy alone versus radical prostatectomy following neoadjuvant hormonal therapy at Memorial Sloan-Kettering Cancer Center between October 1991 and August 1996. Patient data related to prostatic Intraepithelial Neoplasia were analyzed. Of 275 evaluable patients 145 (52.7%) had prostatic Intraepithelial Neoplasia. Of 50 patients treated with neoadjuvant hormonal therapy (hormone group) 22 (44%) had a lower incidence of prostatic Intraepithelial Neoplasia compared to 69 of 80 controls (86.3%) (chi-square test p<0.0001). Of 262 patients (95.3%) with followup PSA 44 (16.8%) had PSA recurrence at a median followup of 32 months, with a median time to recurrence of 30 months. PSA recurrence was noted in 23 of 145 patients with compared to 21 of 130 without prostatic Intraepithelial Neoplasia (chi-square test p = 0.95), and did not significantly differ between the hormone group (25 of 142, 17.6%) and controls (19 of 130, 14.6%) (chi-square test p = 0.45). While patients treated with neoadjuvant hormonal therapy had significantly lower incidence of prostatic Intraepithelial Neoplasia, neither prostatic Intraepithelial Neoplasia nor neoadjuvant hormonal therapy significantly affected PSA recurrence at a median followup of 32 months.